International Flavors & Fragrances Inc. Q2 FY2026 earnings call

• Portfolio Transformation & Divestitures

  • IFF agreed to divest its food ingredients business to CVC Capital Partners for an enterprise value of $4.3 billion (10x EV/EBITDA), with transaction close expected by the end of Q2 2027.
  • IFF will retain a 10% ownership stake in the divested food ingredients business to maintain collaborative opportunities and allow shareholders to participate in future value creation.
  • A second divestiture of non-strategic botanical extracts, vitamins, minerals, and food enhancement products (generating ~$170 million in annual revenue with a mid-single-digit EBITDA margin) was announced, expected to close in Q4 2026 for ~$75 million in proceeds.
  • Post-divestiture, IFF will be focused on three higher-growth, higher-margin core businesses: Taste, Scent, and Health & Biosciences, aligned with long-term megatrends in health, well-being, sustainability, and consumer food preferences.

• Capital Allocation

  • Net proceeds from the food ingredients divestiture will be allocated as: >$1 billion to debt reduction to reach a target net debt to credit-adjusted EBITDA leverage range of 2.0x to 2.5x by the end of 2027, and $2.5 billion for a new share repurchase program (including the $400 million remaining from the prior authorization).
  • Approximately $500 million of share repurchases are expected to be executed in H2 2026 ahead of transaction close, with the remaining $2 billion completed by the end of 2027 after close.
  • Any remaining proceeds will be reinvested in high-return growth opportunities across the core portfolio.

• Stranded Cost Remediation

  • Approximately $100 million in annual stranded corporate and functional costs previously allocated to food ingredients will remain with IFF post-close, temporarily pressuring segment margins.
  • Management has an active remediation plan in place, targeting elimination of two-thirds of these costs within 12 months of close, and the remaining third by the end of the second full year post-close, to support long-term EBITDA margin expansion.

• Financial Performance (First Half 2026, Continuing Operations)

  • Sales grew 4% year-over-year, and EBITDA grew 8% year-over-year, driven by volume growth and productivity improvements.
  • Free cash flow totaled $378 million, a $284 million year-over-year increase, driven by strong working capital improvements from better inventory management and more disciplined accounts receivable/payable controls.
  • At the end of Q2 2026, net debt to credit-adjusted EBITDA stood at 2.5x, down significantly from 4.5x at the start of 2024.

1. Taste: Revenue grew 4% to $688 million, representing 35% of continuing operations total Q2 revenue. EBITDA increased 6% to $124 million. Growth was broad-based across all regions, led by double-digit growth in Asia, driven by strong new business wins and existing business volume increases. Profitability growth was supported by volume gains and favorable net pricing.
2. Health & Biosciences: Revenue grew 5% to $601 million, representing 31% of continuing operations total Q2 revenue. EBITDA increased 6% to $150 million. Growth was seen across all sub-businesses, with notable expansion in grain processing, food biosciences, and animal nutrition. Profitability growth was driven primarily by volume leverage.
3. Scent: Revenue grew 8% to $665 million, representing 34% of continuing operations total Q2 revenue. EBITDA increased 5% to $134 million. Growth was led by double-digit expansion in fragrance ingredients, high single-digit growth in consumer fragrance, and low single-digit growth in fine fragrance (which reflected ongoing impacts from the Middle East conflict). Profitability growth was driven by volume gains and productivity improvements.

• Full year 2026 guidance is now provided on a continuing operations basis (excluding food ingredients), reflecting the completed divestiture announcement and strong first half performance.
• Full year 2026 sales guidance is revised to $7.4 billion to $7.6 billion, representing 2% to 4% year-over-year growth, an upward revision to the low end of the prior 1% to 4% growth range driven by solid H1 performance.
• Full year 2026 EBITDA guidance is set at $1.53 billion to $1.60 billion, representing 4% to 8% year-over-year growth, an upward revision to the low end of the prior 3% to 8% growth range.
• Foreign exchange is expected to add approximately 1 percentage point to full year 2026 sales growth and 2 percentage points to full year 2026 EBITDA growth.
• The implied second half 2026 growth range is 0% to 4% for sales and 4% to 8% for EBITDA, with growth expected to moderate from the 6% Q2 sales growth rate but remain solid.
• Full year 2026 free cash flow is expected to be higher than 2025 levels, even after accounting for an estimated ~$200 million in working capital headwinds related to the food ingredients divestiture separation process in H2 2026.
• Long-term, core continuing operations are expected to deliver free cash flow (defined as (EBITDA - CapEx)/sales) in the mid-to-high teens percentage range, up from the lower cash generation of the divested food ingredients business.
• CapEx for continuing operations is expected to average 5% to 6% of sales annually, with the rate trending toward the upper end of this range over the next 1-2 years to fund high-return strategic growth initiatives.

• Ongoing macroeconomic and market uncertainty, including continued volatility related to the ongoing Middle East conflict, which has negatively impacted fine fragrance demand and creates broader visibility challenges.
• Persistent and renewed inflationary pressures on input costs (raw materials, energy, logistics), which may create temporary pricing lags and require negotiation with customers to pass through cost increases.
• Transaction-related working capital headwinds in H2 2026 related to the food ingredients divestiture, including required unwinding of factoring agreements, inventory builds, and supplier prepayments to ensure business continuity during the transition, with the ultimate magnitude dependent on separation timing.
• Chinese competitive pressure in IFF's core end markets, requiring continued innovation investment to maintain competitive moats.
• Consumer demand shifts related to GLP-1 use and trends away from ultra-processed foods, which create uncertainty for IFF's taste and food biosciences businesses, though management has framed this as an opportunity to grow through product innovation for healthier consumer products.

Q: After the food ingredients divestiture, are more portfolio trims expected, or is this the last major deal?

A: Management stated that after two and a half years of portfolio transformation to focus on the three high-innovation core businesses of Scent, Taste, and Health & Biosciences, IFF is now positioned exactly where it wants to be. No additional significant divestitures are planned, and the focus going forward will be on scaling the core businesses organically.

Q: What drove the upward revision to the low end of the full year sales growth guidance, and what is the implied second half growth outlook?

A: The upward adjustment to the guidance range primarily reflects the flow-through of the stronger-than-expected 4% year-over-year sales growth in the first half of 2026. Management expects sales growth to moderate from the 6% Q2 rate in the second half, targeting low single-digit growth, and maintained a wide guidance range to account for ongoing market uncertainty, not as a signal of weaker underlying demand for the core business.

Q: How much of the double-digit growth in fragrance ingredients came from easy year-over-year comparisons, and what is the outlook for recovery after the Middle East conflict?

A: Around half of the 20%+ Q2 growth in fragrance ingredients came from a easy comparison to a 10%+ decline in the year-ago quarter, with the other half from the team strategically capturing additional sales of synthetics amid supply chain disruptions and high crude prices. Growth is expected to normalize in the second half, shifting back toward higher-value added ingredients. Fine fragrance outperformed Q2 expectations (finished slightly positive) despite Middle East headwinds, and while Q3 will face a tough 20% year-ago comparison, management expects a recovery in Q4 2026.

Q: Why is stranded cost remediation split over two years instead of addressing all $100 million in year one, and what is the long-term EBITDA margin outlook for the remaining business?

A: Management opted for a two-phase plan to eliminate the $100 million in stranded costs (two-thirds in year one, the rest in year two) to avoid disrupting profitable growth for the three core businesses. The gradual approach enables disciplined cost cutting without harming ongoing commercial and innovation operations, and the plan is expected to deliver clear EBITDA margin expansion over the period as the stranded costs are eliminated.

Q: Why is R&D spending staying at ~9% of sales rather than increasing with divestiture proceeds, especially in the face of growing Chinese competition?

A: Management noted that it does not underestimate Chinese competitors and is committed to competing rigorously, with R&D spend already increasing from 7% of sales for the remaining core businesses pre-divestiture to 9% currently. R&D spend will continue to rise in absolute terms as sales grow, and management is open to increasing R&D as a percentage of sales if high-value-return opportunities that create additional shareholder value are identified.